NCT01987830View on ClinicalTrials.gov

Bevacizumab w / Temozolomide PET & Vascular MRI For GBM

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Recurrent Glioblastoma
Interventions
DEVICE

MRI-PET

"* \[11C\] temozolomide for PET scan and a contrast dye for the MRI scan~* Drawing blood to assess the radioactivity of \[11C\] temozolomide"

DEVICE

TMZ-PET

The PET scan will take approximately 90 minutes. You will receive one injection of \[11C\] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.

Trial Locations (1)

02215

Massachuesett General Hospital, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Massachusetts General Hospital

OTHER

NCT01987830 - Bevacizumab w / Temozolomide PET & Vascular MRI For GBM | Biotech Hunter | Biotech Hunter